⚠️ Research Use Only — This product is intended for in vitro research purposes only. Not for human consumption or clinical use. Consult a licensed physician for medical advice.

Retatrutide in Bali: Triple-Agonist Research Peptide

Retatrutide (LY3437943) is a novel triple-agonist peptide that activates GLP-1, GIP, and glucagon receptors simultaneously. Clinical trials have demonstrated unprecedented weight loss outcomes, making it a compound of significant research interest in metabolic science.

What is Retatrutide?

Retatrutide is a synthetic peptide developed by Eli Lilly as an investigational treatment for obesity and type 2 diabetes. Unlike earlier GLP-1 receptor agonists (semaglutide, liraglutide) or dual agonists (tirzepatide), retatrutide simultaneously activates three distinct metabolic pathways:

• GLP-1 receptor agonism → Enhances insulin secretion, suppresses glucagon, delays gastric emptying
• GIP receptor agonism → Amplifies insulin response, may improve fat metabolism and satiety
• Glucagon receptor agonism → Increases energy expenditure, promotes fat oxidation, reduces hepatic lipid accumulation

This triple-agonist mechanism represents a distinct approach from current GLP-1 monotherapies and GLP-1/GIP dual agonists.

Clinical Trial Data (Phase 2)

The landmark Phase 2 trial published by Jastreboff et al. (2023) in the New England Journal of Medicine evaluated retatrutide in 338 adults with obesity over 48 weeks:

The 12 mg dose cohort achieved a mean weight reduction of 24.2% at 48 weeks—the highest ever reported in a clinical trial for any pharmacological obesity intervention. For context:

• Semaglutide (Wegovy 2.4 mg): ~15% weight loss at 68 weeks
• Tirzepatide (Zepbound 15 mg): ~22% weight loss at 72 weeks
• Retatrutide 12 mg: ~24% weight loss at 48 weeks

Mechanism: Why Three Receptors?

The addition of glucagon receptor agonism to the GLP-1/GIP framework is the key differentiator. While glucagon is traditionally associated with raising blood glucose, when combined with GLP-1 and GIP in retatrutide's engineered peptide sequence:

• Energy expenditure increases → Glucagon receptor activation in adipose tissue promotes thermogenesis and fat oxidation
• Hepatic fat clearance → Reduces steatosis without elevating blood glucose (GLP-1 counterbalances glucagon's glycemic effects)
• Enhanced lipolysis → Mobilizes stored fat more aggressively than GLP-1 alone

This synergistic effect explains why retatrutide outperforms dual agonists in preclinical models and early human trials.

Research Applications

Retatrutide is being investigated for:

• Obesity pharmacotherapy — Mechanisms of unprecedented weight loss via triple-agonism
• Metabolic syndrome — Effects on insulin sensitivity, lipid profiles, and hepatic steatosis
• Type 2 diabetes — Glycemic control beyond current incretin therapies
• NASH/NAFLD — Glucagon's role in hepatic fat metabolism
• Cardiovascular outcomes — Ongoing Phase 3 trials (TRIUMPH program) examining CV safety and benefits

Dosing Protocols (Research Context)

Clinical trials used a dose-escalation protocol to minimize gastrointestinal side effects:

• Weeks 1-4: 2 mg subcutaneous once weekly
• Weeks 5-8: 4 mg once weekly
• Weeks 9-12: 8 mg once weekly
• Week 13+: 12 mg once weekly (maintenance dose)

Gradual titration reduced discontinuation rates due to nausea, vomiting, and diarrhea (common with all GLP-1 agonists). Even at 12 mg, retatrutide's tolerability profile was comparable to lower-dose semaglutide.

Comparison: Retatrutide vs. Semaglutide vs. Tirzepatide

Retatrutide achieved greater weight loss in less time, suggesting accelerated fat loss via glucagon-mediated energy expenditure.

Side Effect Profile

Like all GLP-1 receptor agonists, retatrutide's most common adverse effects are gastrointestinal:

• Nausea (most common in escalation phase)
• Diarrhea
• Vomiting
• Constipation

In the Phase 2 trial, GI side effects were dose-dependent but manageable with gradual titration. Serious adverse events were rare (~1% across all doses).

Availability in Indonesia

Retatrutide is currently investigational and not approved by BPOM (Indonesia's drug regulatory authority) or the FDA. It is legal to purchase research-grade peptides in Indonesia for non-human, in vitro research purposes.

BioRelix supplies research-grade retatrutide synthesized by third-party laboratories with HPLC purity verification (≥98%). Our product is:

• Not manufactured by Eli Lilly
• Not a pharmaceutical-grade drug
• Not approved for clinical use in humans
• Intended solely for in vitro research

Storage and Reconstitution

Retatrutide is supplied as lyophilized powder and requires reconstitution with bacteriostatic water:

• Unreconstituted: Store at 2-8°C (refrigerator) or -20°C (freezer for long-term storage)
• Reconstituted: Store at 2-8°C, use within 28 days
• Avoid: Freezing after reconstitution, exposure to light, temperature fluctuations

For detailed reconstitution instructions, see our Peptide Reconstitution Guide.

Research Context: What's Next for Retatrutide?

Eli Lilly's Phase 3 TRIUMPH program is currently enrolling patients for cardiovascular outcomes and obesity treatment trials. If successful, retatrutide could receive FDA approval as early as 2026-2027. Until then, it remains an investigational compound available only for research purposes.

References

1. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. doi:10.1056/NEJMoa2301972
2. Thomas MK, Nikooienejad A, Bray R, et al. Dual GIP and GLP-1 receptor agonist tirzepatide improves beta-cell function and insulin sensitivity in type 2 diabetes. J Clin Endocrinol Metab. 2021;106(2):388-396.
3. Müller TD, Finan B, Bloom SR, et al. Glucagon-like peptide 1 (GLP-1). Mol Metab. 2019;30:72-130.
4. Brandt SJ, Götz A, Tschöp MH, Müller TD. Gut hormone polyagonists for the treatment of type 2 diabetes. Peptides. 2018;100:190-201.

⚠️ Reminder: This product is for research use only. Not for human consumption or clinical use. Always consult a licensed physician for medical advice regarding obesity, diabetes, or metabolic conditions.